Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Sexual Health Reports
Published in: Current Sexual Health Reports 2/2017

01-06-2017 | Male Sexual Dysfunction and Disorders (AW Pastuszak and TS Köhler, Section Editors)

Effects of Testosterone on Benign and Malignant Conditions of the Prostate

Authors: Amin S. Herati, Taylor P. Kohn, Peter R. Butler, Larry I. Lipshultz

Published in: Current Sexual Health Reports | Issue 2/2017

Login to get access

Abstract

Purpose of the Review

This review summarizes the current literature regarding the effects of testosterone therapy (TTh) on common disorders of the prostate.

Recent Findings

Testosterone therapy has gained credibility over the last several decades as a potentially safe co-treatment modality for men with benign and malignant prostatic conditions. Our understanding of the effects of testosterone on the prostate continues to evolve with on-going clinical and basic science research. Findings of these studies have reinvigorated the debate over the effects of testosterone on benign and malignant disorders of the prostate, including BPH, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and prostate cancer.

Summary

Despite the burgeoning body of data claiming the safety and efficacy of TTh in common prostatic conditions (including BPH, CP/CPPS, and prostate cancer), diligent monitoring, appropriate patient selection, and informed consent are critical until more definitive studies are performed.
Literature
1.
Handelsman DJ. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199(8):548–51.CrossRefPubMed
2.
Desroches B, Kohn TP, Welliver C, Pastuszak AW. Testosterone therapy in the new era of Food and Drug Administration oversight. Transl Androl Urol. 2016;5(2):207–12.CrossRefPubMedPubMedCentral
3.
•• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4):232–40. This historical study reported regression of prostate cancer with testosterone reduction and conversly that administration of testosterone caused prostate cancer to grow CrossRefPubMed
4.
Prout Jr GR, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer. 1967;20(11):1871–8.CrossRefPubMed
5.
Fowler Jr JE, Whitmore Jr WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126(3):372–5.PubMed
6.
Ho SM, Damassa D, Kwan PW, Seto HS, Leav I. Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated Noble rats. J Androl. 1985;6(5):279–90.CrossRefPubMed
7.
Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161(4):1174–9.CrossRefPubMed
8.
Holmang S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993;23(2):99–106.CrossRefPubMed
9.
Bhasin S, Parker RA, Sattler F, Haubrich R, Alston B, Umbleja T, et al. Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab. 2007;92(3):1049–57.CrossRefPubMed
10.
Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55(1):121–30.CrossRefPubMed
11.
Sih R, Morley JE, Kaiser FE, Perry HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82(6):1661–7.CrossRefPubMed
12.
Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001;56(5):M266–72.CrossRefPubMed
13.
Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134–43.CrossRefPubMedPubMedCentral
14.
Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61.CrossRefPubMed
15.
Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015:jc20144434.
16.
Meuleman EJ, Legros JJ, Bouloux PM, Johnson-Levonas AO, Kaspers MJ, Elbers JM, et al. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. The aging male : the official journal of the International Society for the Study of the Aging Male. 2015:1–7.
17.
Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian journal of andrology. 2015;
18.
Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64(5):811–22.CrossRefPubMed
19.
Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol. 2016;
20.
Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl. 2002;25(2):119–25.CrossRefPubMed
21.
Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. The Aging Male: The Official Journal of the International Society for the Study of the Aging Male. 2011;14(1):53–8.CrossRef
22.
Meikle AW, Stephenson RA, Lewis CM, Middleton RG. Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. J Clin Endocrinol Metab. 1997;82(2):571–5.PubMed
23.
DeLay KJ, Kohler TS. Testosterone and the prostate: artifacts and truths. Urol Clin North Am. 2016;43(3):405–12.CrossRefPubMed
24.
Herati AS, Moldwin RM. Prostatitis, chronic nonbacterial, inflammatory and Noninflammatory (NIH CP/CPPS IIIA AND IIIB). In: Gomella LG, editor. 5-minute urology consult. 1. 3RD ed. Philadelphia: Wolters Kluwer; 2015. p. 356–7.
25.
McNaughton Collins M, Pontari MA, O'Leary MP, Calhoun EA, Santanna J, Landis JR, et al. Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med. 2001;16(10):656–62.CrossRefPubMedPubMedCentral
26.
Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol. 2008;179(5 Suppl):S61–7.CrossRefPubMed
27.
Mehik A, Hellstrom P, Nickel JC, Kilponen A, Leskinen M, Sarpola A, et al. The chronic prostatitis-chronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements. J Urol. 2002;167(1):137–40.CrossRefPubMed
28.
Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol. 2003;170(6 Pt 1):2517–22.CrossRefPubMed
29.
Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen MW, Burchardt T, et al. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity. J Urol. 1999;162(4):1527–31.CrossRefPubMed
30.
Tsilidis KK, Rohrmann S, McGlynn KA, Nyante SJ, Lopez DS, Bradwin G, et al. Association between endogenous sex steroid hormones and inflammatory biomarkers in US men. Andrology. 2013;1(6):919–28.CrossRefPubMed
31.
Byun JS, Yoon TK, Rhee HW, Kim JH, Shin JS, Kim HS, et al. Chronic pelvic pain syndrome and semen quality of Korean men in their fourth decade. J Androl. 2012;33(5):876–85.CrossRefPubMed
32.
Lee JH, Lee SW. Testosterone and chronic prostatitis/chronic pelvic pain syndrome: a propensity score-matched analysis. J Sex Med. 2016;13(7):1047–55.CrossRefPubMed
33.
34.
Golabek T, Belsey J, Drewa T, Kolodziej A, Skoneczna I, Milecki P, et al. Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer. Cent European J Urol. 2016;69(2):131–8.PubMedPubMedCentral
35.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.CrossRefPubMed
36.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.CrossRefPubMed
37.
Thirumalai A, Cooper LA, Rubinow KB, Amory JK, Lin DW, Wright JL, et al. Stable Intraprostatic dihydrotestosterone in healthy medically castrate men treated with exogenous testosterone. J Clin Endocrinol Metab. 2016;101(7):2937–44.CrossRefPubMed
38.
Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM. Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology. 2003;144(7):2922–32.CrossRefPubMed
39.
Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68(6):1263–7.CrossRefPubMed
40.
Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol. 2000;163(3):824–7.CrossRefPubMed
41.
Garcia-Cruz E, Piqueras M, Ribal MJ, Huguet J, Serapiao R, Peri L, et al. Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia. BJU Int. 2012;110(6 Pt B):E199–202.CrossRefPubMed
42.
Garcia-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, et al. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment. BJU Int. 2012;110(11 Pt B):E541–6.CrossRefPubMed
43.
Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005;174(6):2178–80.CrossRefPubMed
44.
Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer. 2011;117(17):3953–62.CrossRefPubMed
45.
Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology. 2008;72(6):1240–5.CrossRefPubMed
46.
Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52(3):696–701.CrossRefPubMed
47.
Morgentaler A. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med. 2009;6(2):574–7.CrossRefPubMed
48.
Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila Jr D, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256–60.CrossRefPubMed
49.
Morales A. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry. BJU Int. 2011;107(9):1369–73.CrossRefPubMed
50.
San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol. 2011;185(2):471–6.CrossRefPubMed
51.
Kacker R, Hult M, San Francisco IF, Conners WP, Rojas PA, Dewolf WC, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian journal of andrology. 2016;18(1):16–20.CrossRefPubMed
52.
Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2.CrossRefPubMed
53.
Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173(2):533–6.CrossRefPubMed
54.
Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639–44.CrossRefPubMedPubMedCentral
55.
Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536–41.CrossRefPubMed
56.
Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer. BJU Int. 2014;114(1):125–30.CrossRefPubMed
57.
Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25(1):24–8.CrossRefPubMed
58.
Wadosky KM, Koochekpour S. Therapeutic rationales, progresses, failures, and future directions for advanced prostate cancer. Int J Biol Sci. 2016;12(4):409–26.CrossRefPubMedPubMedCentral
59.
Kokontis JM, Hay N, Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol. 1998;12(7):941–53.CrossRefPubMed
60.
Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A. 1996;93(21):11802–7.CrossRefPubMedPubMedCentral
61.
62.
Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell. 2009;139(6):1069–83.CrossRefPubMedPubMedCentral
63.
Haffner MC, Aryee MJ, Toubaji A, Esopi DM, Albadine R, Gurel B, et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet. 2010;42(8):668–75.CrossRefPubMedPubMedCentral
64.
Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol. 2009;56(2):237–44.CrossRefPubMedPubMedCentral
65.
Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009;56(1):97–103.CrossRefPubMedPubMedCentral
66.
• Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7(269):269ra2. This study demonstrated pilot data for a novel therapeutic approach to the treatment of asymptomatic castration-resistant prostate cancer by targeting the androgren receptor overexpression CrossRefPubMedPubMedCentral
Metadata
Title
Effects of Testosterone on Benign and Malignant Conditions of the Prostate
Authors
Amin S. Herati
Taylor P. Kohn
Peter R. Butler
Larry I. Lipshultz
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Sexual Health Reports / Issue 2/2017
Print ISSN: 1548-3584
Electronic ISSN: 1548-3592
DOI
https://doi.org/10.1007/s11930-017-0104-7

Other articles of this Issue 2/2017

Current Sexual Health Reports 2/2017 Go to the issue

Current Controversies (P Kleinplatz and C Moser, Section Editors)

To Transition or Not to Transition? That Is the Question

Preclinical and Psychophysiology (F Guarraci and L Marson, Section Editors)

Translating Penile Erectile Hydraulics to Clinical Application in Inflatable Penile Prosthesis Implant

Male and Female Surgical Interventions (A Burnett and C Carson, Section Editors)

Postmarketing Experience of Intralesional Collagenase Clostridium histolyticum (Xiaflex®) Injection in Men with Peyronie’s Disease

Integrating the Psychosocial (B McCarthy, RT Segraves and AH Clayton, Section Editors)

The Dual Control Model of Sexual Response: Relevance of Sexual Excitation and Sexual Inhibition for Sexual Function